335 related articles for article (PubMed ID: 26558647)
1. The role of adjuvant therapy in uterine leiomyosarcoma.
Ducie JA; Leitao MM
Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
[TBL] [Abstract][Full Text] [Related]
2. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Ricci S; Stone RL; Fader AN
Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
5. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyosarcoma metastasizing to the heart.
Tunio MA; Al-Asiri M; Fareed MM
J Coll Physicians Surg Pak; 2014 Mar; 24 Suppl 1():S20-1. PubMed ID: 24717993
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute.
Kodama K; Sonoda K; Kijima M; Yamaguchi S; Yagi H; Yasunaga M; Ohgami T; Onoyama I; Kaneki E; Okugawa K; Yahata H; Ohishi Y; Oda Y; Kato K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e63-e67. PubMed ID: 31721462
[TBL] [Abstract][Full Text] [Related]
9. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced uterine leiomyosarcoma.
Hyman DM; Grisham RN; Hensley ML
Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
[TBL] [Abstract][Full Text] [Related]
11. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
12. Uterine leiomyosarcoma: A review of the literature and update on management options.
Roberts ME; Aynardi JT; Chu CS
Gynecol Oncol; 2018 Dec; 151(3):562-572. PubMed ID: 30244960
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment in adult uterine sarcomas.
Desar IME; Ottevanger PB; Benson C; van der Graaf WTA
Crit Rev Oncol Hematol; 2018 Feb; 122():10-20. PubMed ID: 29458779
[TBL] [Abstract][Full Text] [Related]
14. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
Diggs A; Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Hershman DL; Wright JD
Gynecol Oncol; 2022 Aug; 166(2):308-316. PubMed ID: 35660331
[TBL] [Abstract][Full Text] [Related]
15. Trends in the treatment of uterine leiomyosarcoma in the Medicare population.
Foley OW; Rauh-Hain JA; Clemmer J; Clark RM; Hall T; Diver EJ; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2015 Mar; 25(3):453-8. PubMed ID: 25628107
[TBL] [Abstract][Full Text] [Related]
16. A review of treatment of uterine leiomyosarcomas.
Reed N
Curr Oncol Rep; 2013 Dec; 15(6):581-7. PubMed ID: 24136566
[TBL] [Abstract][Full Text] [Related]
17. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
18. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
19. Uterine sarcomas--recent progress and future challenges.
Seddon BM; Davda R
Eur J Radiol; 2011 Apr; 78(1):30-40. PubMed ID: 21247711
[TBL] [Abstract][Full Text] [Related]
20. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
